Delivering and maintaining optimal DPI performance  

Demand for inhaled therapeutics continues to grow steadily with estimates suggesting that the market for respiratory inhalers will reach a value of 41.4 billion USD by 2030. Rising rates of respiratory illnesses such as asthma and chronic obstructive pulmonary disease are the primary driver of growth. Pressurized metered dose or dry powder inhalers (pMDIs or DPIs) are the ‘go to’ choice for treating these conditions. Hence, systemic drug delivery via the pulmonary route continues to attract considerable attention.

In this whitepaper, we'll look at requirements for moisture control in dry powder inhaler development and a definition of desiccant packaging solutions.